ID: 436
Titel: En randomiserad, öppen, klinisk multicenterstudie som jämför effektivitet och säkerhet för antikropp–läkemedelskonjugatet SYD985 med läkarens val hos patienter med icke-resektabel lokalt avancerad eller metastaserande HER2-positiv bröstcancer
Provsamlingsansvarig: Leif Klint
Start insamling: 2018-09-01
Slut insamling: 2019-05-31
Beskrivning: To qualify for the study the patient's cancer cells should have a minimal level of HER2 protein expression. 
Archival tumour material should be submitted to the central pathology laboratory during screening for HER2 testing. If no archived tumour material is available a biopsy should be performed to obtain tumour material.  
Since due to local procedures it is not possible to submit a tumour block, 15 unstained freshly cut slides of 4 µm should be submitted. Preparation of tissue should be performed as detailed in the Central Laboratory Manual. 
The slide will be kept at the central laboratory until study end and then destroyed.

PROVTYP;PROVGIVARE
Tumörvävnad;10